Liraglutide (Hangzhou Heze)

Primary study objective To investigate the pharmacokinetics of a single subcutaneous injection of the test preparation liraglutide injection (specification: 3 mL:18 mg, Jiangsu Notai Ausino Biopharmaceutical Co., Ltd.) and the reference preparation liraglutide injection (trade name: Victoza, specification: 3 mL:18 mg, Novo Nordisk A/S, Denmark) in healthy adult subjects under fasting conditions, and to evaluate the bioequivalence of the two preparations. Secondary study objective To evaluate the safety of a single subcutaneous injection of the test preparation (T) liraglutide injection and the reference preparation (R) liraglutide injection (Victoza) in healthy subjects under fasting conditions.